CA3051828A1 - Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor - Google Patents
Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor Download PDFInfo
- Publication number
- CA3051828A1 CA3051828A1 CA3051828A CA3051828A CA3051828A1 CA 3051828 A1 CA3051828 A1 CA 3051828A1 CA 3051828 A CA3051828 A CA 3051828A CA 3051828 A CA3051828 A CA 3051828A CA 3051828 A1 CA3051828 A1 CA 3051828A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- administered
- amount
- response
- study
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662287858P | 2016-01-27 | 2016-01-27 | |
| US62/287,858 | 2016-01-27 | ||
| PCT/US2017/015237 WO2017132445A1 (en) | 2016-01-27 | 2017-01-27 | Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3051828A1 true CA3051828A1 (en) | 2017-08-03 |
Family
ID=59398691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3051828A Pending CA3051828A1 (en) | 2016-01-27 | 2017-01-27 | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20190111053A1 (enExample) |
| EP (1) | EP3407887B1 (enExample) |
| JP (1) | JP6964593B2 (enExample) |
| CN (1) | CN109475543A (enExample) |
| CA (1) | CA3051828A1 (enExample) |
| WO (1) | WO2017132445A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160004299A (ko) | 2013-04-09 | 2016-01-12 | 릭스트 바이오테크놀로지, 인코포레이티드 | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 |
| JP7187023B6 (ja) | 2015-05-15 | 2023-01-05 | リクスト・バイオテクノロジー，インコーポレイテッド | オキサビシクロヘプタンプロドラッグ |
| US20190240290A1 (en) * | 2016-08-04 | 2019-08-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Companion diagnostic for combination lenalidomide and erythropoietin treatment |
| AU2017370731B2 (en) | 2016-12-08 | 2022-06-02 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for modulation of immune response |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008030617A2 (en) | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer therapy with cantharidin and cantharidin analogs |
| BRPI0806365B8 (pt) | 2007-02-06 | 2021-05-25 | Lixte Biotechnology Holdings Inc | composto, uso do composto, composição farmacêutica e uso da composição farmacêutica |
| KR20160004299A (ko) * | 2013-04-09 | 2016-01-12 | 릭스트 바이오테크놀로지, 인코포레이티드 | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 |
| WO2016014778A1 (en) * | 2014-07-24 | 2016-01-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes |
| US20160074390A1 (en) * | 2014-09-12 | 2016-03-17 | Lixte Biotechnology, Inc. | Human dosing of phosphatase inhibitor |
-
2017
- 2017-01-27 EP EP17744934.5A patent/EP3407887B1/en not_active Not-in-force
- 2017-01-27 CA CA3051828A patent/CA3051828A1/en active Pending
- 2017-01-27 JP JP2018540013A patent/JP6964593B2/ja not_active Expired - Fee Related
- 2017-01-27 WO PCT/US2017/015237 patent/WO2017132445A1/en not_active Ceased
- 2017-01-27 CN CN201780019895.5A patent/CN109475543A/zh active Pending
- 2017-01-27 US US16/072,963 patent/US20190111053A1/en not_active Abandoned
-
2022
- 2022-03-04 US US17/687,231 patent/US20220323433A2/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109475543A (zh) | 2019-03-15 |
| EP3407887B1 (en) | 2021-09-01 |
| US20190111053A1 (en) | 2019-04-18 |
| WO2017132445A1 (en) | 2017-08-03 |
| US20220323433A2 (en) | 2022-10-13 |
| JP2019507134A (ja) | 2019-03-14 |
| EP3407887A1 (en) | 2018-12-05 |
| EP3407887A4 (en) | 2019-09-25 |
| JP6964593B2 (ja) | 2021-11-10 |
| WO2017132445A8 (en) | 2018-12-20 |
| US20220184066A1 (en) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220323433A2 (en) | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
| CN105705148B (zh) | 使用普那布林和紫杉烷的组合的癌症疗法 | |
| KR20230148208A (ko) | 골수섬유증과 같은 혈액 악성종양을 치료하기 위한 bet 억제제 단독 또는 페드라티닙 또는 룩솔리티닙과의 조합물의 용도 | |
| JP5046922B2 (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| JP7047148B2 (ja) | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） | |
| AU2012321106B2 (en) | Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent | |
| KR102613106B1 (ko) | Ｂ―세포 악성종양의 치료를 위한 세르둘라티닙 | |
| AU2016285597A1 (en) | Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer | |
| EP3191096A1 (en) | Human dosing of phosphatase inhibitor | |
| AU2016324920A1 (en) | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia | |
| WO2016168451A1 (en) | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment | |
| US10576050B2 (en) | Methods and compositions for treatment of cancer | |
| WO2022090443A1 (en) | Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor | |
| CN115038447A (zh) | 用于治疗癌症的组合疗法 | |
| KR20150090091A (ko) | 볼라세르티브와의 병용 요법 | |
| TW202034955A (zh) | 使用免疫調節治療癌症之新穎方法 | |
| EP4095137A1 (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma | |
| WO2025103408A1 (zh) | 治疗alk阳性或ros1阳性的非小细胞肺癌的方法 | |
| HK40000014B (en) | Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
| CN1901906B (zh) | 治疗套细胞淋巴瘤的cci-779 | |
| CN116492342B (zh) | 氯喹或羟氯喹在制备治疗尼洛替尼肾脏毒副作用药物中的应用 | |
| HK40085748A (en) | Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma | |
| EP4684788A1 (en) | Pharmaceutical composition and use thereof | |
| EP4729061A1 (en) | Use of akt inhibitor in preparation of drug for preventing or treating breast cancer | |
| WO2023220396A1 (en) | Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220114 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20240729 |
|
| N11 | Application terminated |
Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE Effective date: 20250729 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260318 |